CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

GD2-CART01 Elicits Clinical Activity, Tolerability in Pediatric R/R Neuroblastoma

May 8th 2023

The investigational CAR T-cell therapy GD2-CART01 showed preliminary antitumor activity and safety in pediatric patients with relapsed or refractory high-risk neuroblastoma, according to data from a phase 1/2 trial.

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

May 3rd 2023

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

April 20th 2023

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

Leaked Data Show Cilta-cel Delivers 74% Reduction in Risk of Progression in Early Relapsed/Refractory Myeloma

April 20th 2023

Leaked data from an abstract scheduled to be presented at the 2023 EHA Hybrid Congress showed that ciltacabtagene autoleucel demonstrated a 74% reduction in the risk of disease progression or death compared with standard therapy in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy.

ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC

April 17th 2023

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

Retrospective Study Provides Real-World Insight on Ide-cel in R/R Multiple Myeloma With Renal Impairment

April 11th 2023

Surbhi Sidana, MD, discusses the real-world safety and efficacy of ide-cel in patients with multiple myeloma and renal impairment, and emphasizes the importance of including this population in future clinical trials examining novel therapies in this disease.

CAR T-Cell Therapy Leads to Shorter Hospital Stays, Lower Nonpharmacy Costs Despite High Overall Cost

April 7th 2023

CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them.

FDA Fast Tracks CB-011 for Relapsed/Refractory Multiple Myeloma

April 6th 2023

The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.

FDA Grants Fast Track Designation to SynKIR-110 for Mesothelioma

April 6th 2023

The FDA has granted a fast track designation to SynKIR-110 for the treatment of patients with mesothelioma.

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of select patients with large B-cell lymphoma who relapsed within 12 months from completion of or developed refractory disease to frontline chemoimmunotherapy.

Novel CAR T Utility Must Be Confirmed Across Hematologic Malignancies

March 25th 2023

Craig Sauter, MD, discussed the common limitations of CAR T-cell therapy through timely referral and the existing questions for patients with LBCL who progress on CAR T-cell therapy.

Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma

March 24th 2023

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Investigators identified a set of microbiome-based biomarkers that may be used to optimize patient selection or increase personalization of treatment for patients with B-cell lymphoma receiving CAR T-cell therapy.

Dr Zonder on CAR T-cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Myeloma

March 23rd 2023

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

March 22nd 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Axicabtagene ciloleucel produced a statistically significant improvement in overall survival compared with standard-of-caretherapy in patients with relapsed/refractory large B-cell lymphoma, according to data from the ZUMA-7 trial.

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Mayur Narkhede, MD, discusses the early findings for the use of siltuximab to manage cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in patients following CAR T-cell therapy and expands on the next steps for investigating this agent during the phase 2 trial.

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

Bellicum Pharmaceuticals has discontinued 2 phase 1/2 trials evaluating the safety and preliminary efficacy of the GoCAR T-cell products BPX-601 and BPX-603 in combination with rimiducid in heavily pretreated patients with advanced solid tumors following an assessment of the risk/benefit profile of the combination of BPX-601 and rimiducid.